(Q81118638)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424323%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

title

Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424323%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424323%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Robert B. Huizinga

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424323%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

R Bissonnette

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424323%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

L Rosoph

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424323%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

N Wasel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424323%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

C W Lynde

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424323%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

G Searles

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424323%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

N H Shear

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424323%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

W P Maksymowych

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424323%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

language of work or name

English

0 references

publication date

1 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424323%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424323%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

371

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424323%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

9621

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424323%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

1337-1342

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424323%20AND%20SRC:MED&resulttype=core&format=json

Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960593-0

7 January 2021

Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960593-0

7 January 2021

Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960593-0

7 January 2021

Cyclosporine: what clinicians need to know.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960593-0

7 January 2021

Adverse effects with long-term cyclosporin for severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960593-0

7 January 2021

Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960593-0

7 January 2021

Morphologic renal changes during cyclosporine treatment of psoriasis. Studies on pretreatment and posttreatment kidney biopsy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960593-0

7 January 2021

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960593-0

7 January 2021

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960593-0

7 January 2021

ISATX247: a novel calcineurin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960593-0

7 January 2021

ISA(TX)247: a novel calcineurin inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960593-0

7 January 2021

A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960593-0

7 January 2021

Severe Psoriasis – Oral Therapy with a New Retinoid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960593-0

7 January 2021

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960593-0

7 January 2021

A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960593-0

7 January 2021

10.1016/S0140-6736(08)60593-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424323%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference